Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13988319 | 0.82 | GCK (0.54) | GCK | |
| SCHEMBL12021674 | 0.81 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL12021329 | 0.81 | GCK (0.62) | GCKKCNH2 | |
| SCHEMBL12021505 | 0.81 | GCK (0.62) | GCKKCNH2 | |
| SCHEMBL12021628 | 0.81 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL9072527 | 0.79 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL2658714 | 0.78 | GCK (0.73) | GCKKCNH2 | |
| SCHEMBL3605637 | 0.77 | GCK (0.68) | GCKKCNH2 | |
| SCHEMBL19774536 | 0.77 | GCK (0.73) | GCKKCNH2 | |
| SCHEMBL2658597 | 0.77 | GCK (1.00) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312207-A1 | Compounds | GRK4, PTGER4, GRK5 | GCK 111/4885NPC1 2021/4885RAB9A 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.